描述
An introductory diagram from a review on gut microbiota-targeted therapeutics for metabolic disorders. The figure illustrates the conceptual framework linking dysbiosis to obesity, type 2 diabetes, hyperlipidemia, and non-alcoholic fatty liver disease.
Figure 1
DiagramSource Paper
Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives.Cite This Figure
![Figure 1: An introductory diagram from a review on gut microbiota-targeted therapeutics for metabolic disorders. The figure illustrates the conceptual framework linking dysbiosis to obesity, type 2 diabetes, hyperlipidemia, and non-alcoholic fatty liver disease.]() > Source: Yue Fan et al. "Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insigh." *International journal of molecular sciences*, 2025. PMID: [40564947](https://pubmed.ncbi.nlm.nih.gov/40564947/)
<figure> <img src="" alt="An introductory diagram from a review on gut microbiota-targeted therapeutics for metabolic disorders. The figure illustrates the conceptual framework linking dysbiosis to obesity, type 2 diabetes, hyperlipidemia, and non-alcoholic fatty liver disease." /> <figcaption>Figure 1. An introductory diagram from a review on gut microbiota-targeted therapeutics for metabolic disorders. The figure illustrates the conceptual framework linking dysbiosis to obesity, type 2 diabetes, hyperlipidemia, and non-alcoholic fatty liver disease.<br> Source: Yue Fan et al. "Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insigh." <em>International journal of molecular sciences</em>, 2025. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40564947/">40564947</a></figcaption> </figure>